Larimar Therapeutics, Inc. (LRMR)
NASDAQ · Manufacturing · Pharmaceutical preparations
$3.13−$0.1900 (−5.72%) on the dayAs of the close; data may be delayed.
LRMR price, last 12 months
Key stats
- Previous close
- $3.32
- Open
- $3.38
- Day range
- $3.02 – $3.39
- 52-week range
- $2.72 – $6.42
- Volume
- 2.9M
- Avg volume (20 days)
- 1.3M
- Market cap
- $319.4M
Performance
1W−17.4%
1M−24.9%
3M−14.5%
6M−35.5%
YTD−17.9%
1Y−38.6%
vs S&P 500, 1Y−55.4 pts
Technicals and fundamentals
About Larimar Therapeutics, Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $319.4M